BMC Gastroenterology (Sep 2021)

Tri-modal management of primary small cell carcinoma of the pancreas (SCCP): a rare neuroendocrine carcinoma (NEC)

  • Safa Elzein,
  • Fei Bao,
  • Ray Lin,
  • Gabriel Schnickel,
  • Andrew M. Lowy,
  • Gregory P. Botta

DOI
https://doi.org/10.1186/s12876-021-01901-7
Journal volume & issue
Vol. 21, no. 1
pp. 1 – 7

Abstract

Read online

Abstract Background Primary small cell carcinoma of the pancreas (SCCP) is a rare malignant neuroendocrine carcinoma (NEC). Typically, it presents with lymphovascular invasion as well as metastasis at the time of diagnosis which portends a dismal prognosis. Treatment is typically based on therapy used for other aggressive NECs such as small cell lung cancer. Although multimodal surgery, radiation and chemotherapy may improve prognosis, the outcome generally remains poor. Case presentation Here we present a primary SCCP managed with neoadjuvant multi-agent chemotherapy combined with radiotherapy and surgery Conclusions Multi-disciplinary therapy resulted in an ongoing 28 + month radiographic complete response and overall survival.

Keywords